Research & Development: Page 18

  • Shankar Narayanan, CEO, Real Chemistry
    Image attribution tooltip
    Permission granted by Real Chemistry
    Image attribution tooltip

    Real Chemistry’s CEO on biopharma’s outlook in 2024

    Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

    By • Dec. 7, 2023
  • A CRISPR Therapeutics sign is seen above a door to an office building
    Image attribution tooltip
    Permission granted by CRISPR Therapeutics
    Image attribution tooltip

    CRISPR eyes autoimmune disease in revamp of cell therapy plans

    The gene editing biotech is shelving two of its most advanced cancer drugs, and joining a growing group of companies exploring cell-based medicines for inflammatory diseases like lupus.

    By Ben Fidler • Dec. 6, 2023
  • cancer R&D Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Oncology R&D

    Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

    By PharmaVoice staff
  • dollar sign airplane
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The weight loss market looks unstoppable. How high could it go?

    Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

    By Kelly Bilodeau • Dec. 4, 2023
  • brain maze
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

    A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

    By Kelly Bilodeau • Nov. 29, 2023
  • Header image for "Creating a Compelling IPO Roadshow Presentation"
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biopharma’s top 5 IPOs of 2023 (so far)

    Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

    By Alexandra Pecci • Nov. 28, 2023
  • Cristina Durán, president, Evinova
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Q&A

    The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

    Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.

    By • Nov. 28, 2023
  • Dr. Victoria Zazulina, global head of oncology development, EMD Serono
    Image attribution tooltip
    Permission granted by EMD Serono
    Image attribution tooltip

    How EMD Serono plans to hit its lofty goals in R&D

    The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.

    By Alexandra Pecci • Nov. 27, 2023
  • alcohol bottles illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    As alcohol-related deaths climb, new drugs could curb the urge to drink

    A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

    By Kelly Bilodeau • Nov. 27, 2023
  • Dr. Juan Camilo Arjona Ferreira, chief medical officer, Organon
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip
    Q&A // First 90 Days

    Organon’s chief medical officer wants to change how the world sees women’s health

    Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

    By • Nov. 22, 2023
  • COO, chief operating officer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The biopharma COO’s playbook

    Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

    By Alexandra Pecci • Nov. 21, 2023
  • body muscle
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

    Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

    By Kelly Bilodeau • Nov. 20, 2023
  • man in dark tunnel
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

    The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

    By • Nov. 17, 2023
  • Dr. Paul Moss, deputy head, College of Medical and Dental Sciences, Professor of Haematology, University of Birmingham
    Image attribution tooltip
    Permission granted by AstraZeneca/U. of Birmingham
    Image attribution tooltip
    Q&A

    AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

    Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

    By • Nov. 16, 2023
  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

    By • Nov. 15, 2023
  • Genomics DNA
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The power of genomics-based healthcare remains largely untapped

    23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

    By Alexandra Pecci • Nov. 15, 2023
  • Denise Bronner headshot
    Image attribution tooltip
    Permission granted by Johnson & Johnson Innovative Medicine
    Image attribution tooltip

    6 ways to improve clinical trial diversity — as shown by J&J

    Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

    By Alexandra Pecci • Nov. 14, 2023
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Can Sarepta’s Duchenne gene therapy still deliver on its promise?

    For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

    By Kelly Bilodeau • Nov. 14, 2023
  • moquito art
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

    The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

    By Kelly Bilodeau • Nov. 13, 2023
  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

    By Ned Pagliarulo , • Nov. 9, 2023
  • Anne Wojcicki red carpet
    Image attribution tooltip
    Dia Dipasupil via Getty Images
    Image attribution tooltip
    Q&A

    23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

    23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

    By Alexandra Pecci • Nov. 7, 2023
  • Entrepreneur heeader
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Entrepreneurs

    From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

    By • Nov. 3, 2023
  • Cancer research
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    How Big Pharma keeps the oncology engines hot with a host of strategies

    From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

    By • Nov. 2, 2023
  • robot hand
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls

    From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.

    By Kelly Bilodeau • Nov. 1, 2023
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip

    Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

    Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.

    By • Oct. 31, 2023
  • Dr. Mark Goldberg, CEO and chairman, Allucent
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Dr. Mark Goldberg, a clinical innovator

    Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

    By Alexandra Pecci • Oct. 27, 2023